EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

Sponsor
Fujian Cancer Hospital
Study ID
NCT03720873
Phase
PHASE2
Status
Unknown

Conditions

  • EGFR Gene Mutation

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • erlotinib or gefitinib or icotinib — DRUG
    Patients will be treated with erlotinib 150mgQD or gefitinib250mgQD or icotinib 125 mg TID
  • Anlotinib — DRUG
    Patients will be treated with Anlotinib 12mg po d1-14 Q21d

Study Details

A single arm study: EGFR-TKIs Combine With Anlotinib as First-line Treatment in patients with EGFR-mutant non-small-cell lung cancer (NSCLC).

Key Dates

First listed
Oct 25, 2018
Start date
Oct 31, 2018
Status verified
Oct 2018
Primary completion
Jun 30, 2021
Completion
Sep 30, 2022

Study Design

Enrollment
90 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: EGFR-TKIs and Anlotinib
    Experimental:EGFR-TKIs and Anlotinib EGFR-TKIs:erlotinib 150mg QD or gefitinib250mgQD or icotinib 125 mg TID , Anlotinib 12mg po qd d1-14 q21d

Primary Outcome Measure

Progression free survival [ Time Frame: within 6 months of the last visit of last patient, approximately 30 months after inclusion of first patient ]

Central Contacts

Related Studies